Important notice regarding Inveltys

Posted in Latest News on August 7, 2019.

Important notice regarding Inveltys:

The board approved Inveltys (loteprednol etabonate ophthalmic suspension) 1% for addition to Rule 64B13-18.002. Effective August 5, 2019, Licensees are now permitted to prescribe Inveltys.

← Previous Post Next Post →

More Latest News

Electronic Prescribing Requirements
January 2, 2020

Click here for the new requirements requiring prescribers to generate and transmit all prescriptions electronically Continue reading →

First Quarterly Performance Report Released for the 2019-2020 Fiscal Year
December 16, 2019

The Quarterly Performance Report for the first quarter of the 2019-2020 fiscal year is now available online. Continue reading →